Toxicology – Snake Antivenom: Crotalid and Elapid Envenomation

Core Concept

Snake antivenoms contain antibodies or antibody fragments that bind venom components and limit further venom-mediated injury.

For North American snakes, the two major syndromes are:

• Crotalid (pit viper) envenomation — rattlesnakes, cottonmouths, and copperheads
• Elapid envenomation — especially coral snakes

Modern antivenom practice differs substantially from the older source. The historical whole-IgG equine crotalid antivenom has been replaced in U.S. practice by purified antibody-fragment products with substantially improved tolerability.

Antivenom is most effective at neutralizing circulating or accessible venom; it cannot reliably reverse tissue injury that has already become established.

How Antivenom Works

Antivenom provides passive immunity.

Antibodies or antibody fragments recognize venom molecules and form complexes with them:

Venom toxin + antivenom antibody → neutralized venom complex

This reduces the amount of free venom available to bind its physiologic targets.

Potential benefits include:

• Arresting progression of local tissue effects
• Improving venom-induced coagulopathy
• Reducing systemic toxicity
• Preventing or limiting neurotoxicity

Modern Crotalid Antivenoms

The older source describes an equine whole-IgG product and an investigational ovine Fab product.

That information is outdated.

Modern U.S. crotalid therapy uses purified antibody-fragment antivenoms, principally:

• Ovine Fab antivenom
• Equine F(ab′)₂ antivenom

The old Wyeth whole-IgG crotalid antivenom is no longer the standard contemporary product.

Fab vs F(ab′)₂

Fab

Fab consists of smaller antigen-binding antibody fragments.

Advantages include:

• Rapid distribution
• Lower frequency of severe reactions than historical whole-IgG products

Because Fab fragments are cleared relatively rapidly, recurrent venom effects can occur after initial control.

F(ab′)₂

F(ab′)₂ fragments are larger and generally persist longer in circulation.

Their longer persistence may help maintain venom neutralization and reduce some forms of recurrence.

Both are effective antivenom strategies, but product-specific protocols differ.

Crotalid Envenomation

Pit viper venom is a complex mixture of:

• Proteases
• Phospholipases
• Metalloproteinases
• Hemorrhagic toxins
• Cytotoxic components
• Neurotoxic components in some species/populations

Clinical toxicity varies considerably by snake species, geographic region, venom dose, bite location, and patient factors.

Local Crotalid Effects

Typical local findings include:

• Pain
• Progressive swelling
• Ecchymosis
• Tenderness
• Vesicles or bullae
• Local bleeding
• Tissue injury

Swelling may extend progressively beyond the bite site.

Serial examination is more useful than a single measurement.

Hematologic Toxicity

Crotalid venom can cause a characteristic venom-induced coagulopathy.

Possible findings include:

• Hypofibrinogenemia
• Elevated PT/INR
• Thrombocytopenia
• Increased fibrin degradation
• Clinical bleeding

The pattern does not necessarily behave exactly like conventional disseminated intravascular coagulation.

Systemic Crotalid Effects

Severe envenomation may produce:

• Nausea and vomiting
• Weakness
• Diaphoresis
• Hypotension
• Tachycardia
• Altered mental status
• Bleeding
• Shock
• Neurotoxicity with selected rattlesnake venoms

Some rattlesnake populations produce clinically important cranial or respiratory neuromuscular weakness.

When Crotalid Antivenom Is Indicated

Antivenom is generally appropriate when venom effects are progressive or clinically significant, including:

• Progressive swelling or tissue injury
• Significant or worsening coagulopathy
• Thrombocytopenia attributable to envenomation
• Clinically important bleeding
• Hypotension or shock
• Systemic venom effects
• Neurotoxicity

A bite with no evidence of envenomation does not automatically require antivenom.

Dry Bite

A venomous snake can bite without injecting a clinically important amount of venom.

A suspected dry bite may have:

• Fang marks
• Minimal local discomfort
• No progressive swelling
• No systemic findings
• No evolving hematologic abnormalities

Observation is necessary because early absence of toxicity does not always prove that envenomation will remain absent.

Antivenom Treatment Endpoint

The objective is initial control of envenomation, meaning that:

• Local progression has stopped
• Systemic manifestations are improving
• Coagulopathy is stabilizing or improving
• Neurotoxicity is no longer progressing

Treatment should be guided by the patient’s response and the specific antivenom product rather than by an old universal vial count.

Adult vs Pediatric Treatment

A key principle remains valid:

Children do not automatically receive less antivenom simply because they weigh less.

The amount of antivenom required primarily depends on the amount of venom injected, not the patient’s body weight.

A child may actually experience more severe toxicity from the same venom dose because that dose is distributed through a smaller body mass.

Product-specific treatment protocols still apply.

Recurrent Crotalid Toxicity

Venom effects can recur after apparently successful initial treatment.

This is particularly recognized with:

• Coagulopathy
• Thrombocytopenia
• Local swelling

Possible mechanisms include continued absorption of venom from the bite site and differences between venom and antivenom pharmacokinetics.

Recurrent Coagulopathy

A patient whose laboratory abnormalities initially improve can later develop:

• Falling fibrinogen
• Increasing INR
• Recurrent thrombocytopenia

Therefore, selected patients need serial laboratory reassessment after apparent clinical control.

Do Not Treat Laboratory Numbers in Isolation

Coagulation abnormalities should be interpreted together with:

• Bleeding
• Clinical trajectory
• Antivenom already administered
• Time since envenomation
• Fibrinogen
• Platelet count
• PT/INR

Repeat antivenom decisions are best made with poison-center or medical-toxicology guidance.

Compartment Syndrome – Major Modern Correction

Severe crotalid envenomation can produce dramatic swelling and elevated tissue pressures that mimic compartment syndrome.

True compartment syndrome is considerably less common than the appearance of the limb may suggest.

Before fasciotomy, management generally emphasizes:

• Adequate antivenom
• Serial neurovascular examination
• Objective compartment-pressure measurement when clinically necessary
• Specialist consultation

Antivenom should not be delayed in favor of premature fasciotomy.

Unnecessary surgery can worsen venom-associated tissue injury and bleeding.

First Aid for Pit Viper Bites

Appropriate early measures include:

• Move away from the snake
• Keep the patient calm
• Limit unnecessary exertion
• Remove rings, watches, and constricting objects
• Arrange prompt medical evaluation

Avoid:

• Cutting the wound
• Suction
• Electric shock
• Ice
• Chemical application
• Tight arterial tourniquets

Attempting to capture or kill the snake creates additional risk.

Snake Identification

Management should primarily follow the clinical syndrome and geographic context.

Photographs taken from a safe distance may occasionally assist identification.

The patient or bystanders should not handle a snake, even if it appears dead, because reflex bites can occur.

Coral Snake Envenomation

North American coral snakes are elapids.

Their venom predominantly produces neurotoxicity rather than the major local tissue injury and coagulopathy typical of pit vipers.

Coral Snake Venom Mechanism

Coral snake toxins interfere with neuromuscular transmission.

Depending on the toxin, effects may involve pre- or postsynaptic mechanisms.

The consequence is progressive neuromuscular weakness.

Clinical Features of Coral Snake Envenomation

Early local findings may be surprisingly mild.

Neurologic manifestations can include:

• Ptosis
• Diplopia
• Dysarthria
• Dysphagia
• Generalized weakness
• Reduced respiratory muscle strength
• Respiratory failure

This creates an important principle:

A relatively normal-looking bite site does not exclude dangerous coral snake envenomation.

Delayed Neurotoxicity

Neurologic toxicity may be delayed after a coral snake bite.

Therefore, an initially well patient with a credible bite may require prolonged observation and expert consultation.

Waiting for obvious respiratory paralysis before planning treatment is unsafe.

Coral Snake Antivenom

The older source’s product-specific description reflects historical U.S. antivenom availability and should not be assumed to represent current supply.

Availability of coral snake antivenom has changed substantially over time and may vary by region.

For a credible coral snake envenomation:

• Contact a poison center/medical toxicologist early
• Determine current antivenom availability
• Closely monitor neurologic and respiratory function
• Prepare for ventilatory support if weakness progresses

Coral Snake Antivenom Timing

Antivenom can neutralize venom that has not yet irreversibly interacted with its target.

Once substantial neurotoxicity is established, antivenom may prevent further progression but cannot be expected to immediately reverse all toxin already bound at the neuromuscular junction.

This is why early specialist involvement is important.

Respiratory Monitoring in Elapid Envenomation

Serial assessment should include:

• Respiratory rate
• Depth of breathing
• Oxygenation
• Ventilation
• Bulbar function
• Ability to handle secretions
• Objective respiratory muscle testing when appropriate

Pulse oximetry alone may remain normal until relatively late in neuromuscular respiratory failure.

Mechanical Ventilation

When respiratory muscle weakness becomes significant:

Airway protection and mechanical ventilation are lifesaving.

Ventilatory support should not be delayed while waiting for antivenom to reverse established paralysis.

Recovery may require prolonged support depending on toxin characteristics and severity.

Antivenom Hypersensitivity

Because antivenoms contain animal-derived antibody fragments or proteins, acute hypersensitivity remains possible.

Potential manifestations include:

• Urticaria
• Pruritus
• Flushing
• Angioedema
• Bronchospasm
• Hypotension
• Anaphylaxis

Modern purified antivenoms generally have better safety profiles than historical whole-IgG equine preparations.

Anaphylaxis During Antivenom

If anaphylaxis develops:

• Temporarily stop the infusion
• Assess airway, breathing, and circulation
• Give epinephrine as first-line treatment
• Provide oxygen and airway support
• Give IV fluids for hypotension
• Treat bronchospasm appropriately

Antihistamines can help cutaneous symptoms but are not substitutes for epinephrine in anaphylaxis.

Important Correction to the Older Anaphylaxis Regimen

Several aspects of the older source no longer reflect preferred anaphylaxis management.

In particular:

• Epinephrine is the critical first-line medication.
• Routine H2 blockers are not central lifesaving therapy.
• Corticosteroids have delayed effects and should not replace epinephrine.
• Routine subcutaneous epinephrine is not the preferred emergency route.
• IV epinephrine carries substantial dosing-error and dysrhythmia risk and is reserved for appropriately monitored refractory shock/peri-arrest circumstances managed by experienced clinicians.

Should Antivenom Be Restarted After a Reaction?

If envenomation remains dangerous, a hypersensitivity reaction does not necessarily mean that antivenom can never be given again.

After stabilization, specialists may determine that the benefits of restarting antivenom outweigh the risks.

This is particularly relevant in:

• Progressive systemic toxicity
• Serious coagulopathy
• Shock
• Progressive neurotoxicity

Skin Testing – Important Modern Correction

Historical equine antivenoms were sometimes preceded by intradermal skin testing.

Routine antivenom skin testing is not considered reliable for predicting anaphylaxis and may:

• Delay urgently needed antivenom
• Produce false reassurance
• Produce false-positive results

Modern antivenom administration therefore does not rely on routine predictive skin testing.

Premedication

Routine antihistamine or corticosteroid premedication does not reliably prevent serious antivenom anaphylaxis.

Some protocols or circumstances may use selected premedication, but it should never substitute for:

• Appropriate monitoring
• Immediate access to epinephrine
• Resuscitation capability

Serum Sickness

A delayed immune-complex reaction can occur days after antivenom exposure.

Symptoms may include:

• Fever
• Rash
• Pruritus
• Arthralgia
• Malaise

Less commonly, more significant systemic manifestations can occur.

Serum Sickness and Modern Products

The risk varies according to:

• Antivenom product
• Animal source
• Amount administered
• Degree of purification

Modern Fab and F(ab′)₂ products generally have substantially different adverse-effect profiles from historical whole-IgG horse antivenoms.

Therefore, the very high serum-sickness percentages quoted for old equine products should not be generalized to current antivenoms.

Pregnancy

Pregnancy is not a contraindication to indicated antivenom.

Maternal envenomation can cause:

• Shock
• Coagulopathy
• Hemorrhage
• Placental complications
• Fetal hypoxia
• Pregnancy loss

When significant envenomation is present, effective maternal treatment generally provides the best chance of protecting both mother and fetus.

Laboratory Monitoring for Crotalid Bites

Depending on severity, monitoring may include:

• CBC
• Platelet count
• PT/INR
• Fibrinogen
• Hemoglobin
• Renal function
• Electrolytes
• Creatine kinase when significant muscle injury is suspected
• Urinalysis when indicated

Serial measurements are more informative than a single set of laboratory results.

Blood Products

Venom-induced coagulopathy is fundamentally caused by active venom.

Therefore:

Antivenom is the mechanism-directed treatment.

Blood products may be required for serious active bleeding or selected critical situations, but replacing coagulation components without adequately neutralizing venom can provide only transient benefit.

Local Wound Care

The affected extremity should undergo:

• Serial examination
• Marking/monitoring of swelling progression when useful
• Neurovascular assessment
• Appropriate wound care
• Tetanus assessment

Routine prophylactic antibiotics are generally not required for uncomplicated snakebite unless there is a specific infection-related indication.

What Antivenom Cannot Do

Antivenom can stop or limit ongoing venom activity, but it cannot reliably reverse:

• Established tissue necrosis
• Completed neurologic injury
• Damage caused by prolonged shock
• Secondary complications already established

Therefore, earlier treatment of clinically important progressive envenomation is generally preferable.

Geography Matters

The antivenoms described in the older chapter are specific to North American species.

Snake venom composition and antivenom effectiveness vary dramatically worldwide.

An antivenom designed for one group of snakes cannot be assumed to neutralize unrelated species.

Management of bites outside North America requires:

• Regional species knowledge
• Locally appropriate antivenom
• Poison-center/toxicology expertise where available

Important Modernization of the Older Source

• Historical whole-IgG Wyeth crotalid antivenom is no longer the standard modern U.S. treatment.
• Modern crotalid therapy uses purified Fab or F(ab′)₂ antibody-fragment antivenoms.
• Antivenom is indicated for clinically significant or progressive envenomation, not simply because fang marks are present.
• Pediatric patients generally require venom-directed antivenom treatment rather than automatic weight-based dose reduction.
• Local swelling alone can appear dramatic; true compartment syndrome is uncommon and should not be diagnosed by appearance alone.
• Antivenom and objective assessment should precede unnecessary fasciotomy.
• Recurrent coagulopathy can occur after apparent control, particularly with shorter-lived antibody fragments.
• Coral snake bites may initially produce little local injury while later causing dangerous neuromuscular paralysis.
• Respiratory monitoring is essential in suspected coral snake envenomation.
• Current coral snake antivenom availability must be confirmed rather than relying on historical product descriptions.
• Routine antivenom skin testing is obsolete/unreliable.
• Modern purified products have lower reaction rates than historical whole-IgG equine antivenoms, although anaphylaxis remains possible.
• Epinephrine is first-line treatment for antivenom-associated anaphylaxis.
• Antihistamines and corticosteroids are adjuncts rather than substitutes for epinephrine.
• Serum sickness remains possible but historical rates from older equine antivenom should not be applied directly to modern products.
• Pregnancy is not a reason to withhold indicated antivenom.
• Avoid incision, suction, ice, electric shock, and tight arterial tourniquets.
• Exact vial numbers and infusion protocols are product- and region-specific and should follow current poison-center/toxicology guidance.

Key Points

• Antivenom binds venom and prevents additional toxin from reaching its targets.
• Crotalid bites primarily cause combinations of progressive local injury, coagulopathy, systemic toxicity, and occasionally neurotoxicity.
• Coral snake bites are primarily dangerous because of progressive neuromuscular paralysis and respiratory failure.
• Give antivenom for clinically important or progressive envenomation rather than every venomous-snake bite.
• A normal-looking early coral snake bite does not exclude severe delayed toxicity.
• Children may require the same antivenom amount as adults because the dose is determined mainly by venom burden rather than patient weight.
• Modern Fab and F(ab′)₂ products have replaced older whole-IgG crotalid antivenom in contemporary U.S. practice.
• Anaphylaxis is possible with any antivenom; treatment requires prompt epinephrine and supportive resuscitation.
• Routine predictive skin testing is not recommended.
• Serial examination and laboratory testing are important because venom effects can progress or recur after initial improvement.
• Antivenom choice must match the snake species/geographic region and currently available product.